-

Northlane Capital Partners Invests in SAI MedPartners

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today that it has made an investment in SAI MedPartners (“SAI”), a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. NCP invested in partnership with the SAI management team, led by Founder and CEO Erik Nordhoy.

Headquartered in Reading, Pennsylvania, SAI provides best-in-class competitive intelligence and strategy support services to assist its clients across the product development lifecycle. SAI works with leading multinational pharmaceutical companies, in addition to a growing number of biotechnology and medical device companies. SAI has more than 180 employees located across the United States, Europe, and Asia. Additional information is available at www.sai-med.com.

“We are thrilled to partner with NCP, which has an impressive track record of investing in businesses that support the pharmaceutical and medical device industries. SAI’s rapid organic growth over the past decade has been driven by a singular focus on being the best thought partner and provider of high-quality strategic intelligence and related advisory services to our clients. NCP’s investment will allow us to further strengthen our client engagement model by providing us with the resources to significantly augment our suite of services and continue to expand globally,” said Erik Nordhoy, Founder and CEO of SAI.

Eugene Krichevsky, Partner at NCP, said, “We are delighted to have the opportunity to partner with Erik and rest of the SAI management team. SAI has established itself as a global leader in the life sciences competitive intelligence market. NCP is in complete alignment with SAI’s strategic roadmap of adding resources and expanding the capabilities of the business to increase its value proposition to key customers and stakeholders.”

Justin DuFour, Partner at NCP, added, “SAI is our team’s 30th platform investment and fits squarely in our pharmaceutical services focus within our healthcare vertical. We have significant experience investing in similar business models within SAI’s end markets and look forward to assisting SAI in its next phase of growth.”

ABOUT NORTHLANE CAPITAL PARTNERS

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested more than $1.6 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value. For more information, please visit www.northlanecapital.com.

Contacts

NCP CONTACTS

Eugene Krichevsky, Partner
(301) 841-1399

Justin DuFour, Partner
(301) 841-1375

JJ Carbonell, Principal
(301) 841-1420

Anna Ellingboe, Senior Associate
(301) 272-9992

Northlane Capital Partners


Release Versions

Contacts

NCP CONTACTS

Eugene Krichevsky, Partner
(301) 841-1399

Justin DuFour, Partner
(301) 841-1375

JJ Carbonell, Principal
(301) 841-1420

Anna Ellingboe, Senior Associate
(301) 272-9992

More News From Northlane Capital Partners

SAI MedPartners Enhances Its Competitive Intelligence Capabilities Through the Acquisition of The Dunn Group

READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired The Dunn Group (“TDG”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. TDG, headquartered in Totowa, NJ, is a competitive intelligence firm that focuses on providing primary business intelligence to clients in the pharmaceu...

Northlane Capital Partners Announces Final Close of Oversubscribed Fund III at $750 Million

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“Northlane” or “NCP”) announced today the final closing of its oversubscribed third private equity fund, Northlane Capital Partners III LP (“NCP III” or “Fund III”), at its hard cap of $750 million. The total raised substantially surpassed Fund III’s $550 million target and reflects notable growth from its $408 million predecessor. Global investors include pension funds, insurance companies, endowments and foundations, asset managers,...

Northlane Capital Partners Announces the Sale of Empower Community Care

BETHESDA, Md.--(BUSINESS WIRE)--Northlane Capital Partners (“NCP”) announced today the sale of Empower Community Care (“Empower” or the “Company”) to NexPhase Capital, LP (“NexPhase”). Founded in 2016, Empower is an established global behavioral health organization offering proprietary treatments and services to help at-risk youth, their families, and caregivers. The Company does not directly administer the treatment but instead provides its state and municipal clients with training and support...
Back to Newsroom